Prognostic value of CD133 expression in stage I lung adenocarcinomas

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 1, 2011, Pages 32-42

  Woo, Tetsukan ^a,b   Okudela, Koji ^a   Mitsui, Hideaki ^a   Yazawa, Takuya ^a   Ogawa, Nobuo ^b   Tajiri, Michihiko ^b   Yamamoto, Taketsugu ^a   Rino, Yasushi ^a   Kitamura, Hitoshi ^a   Masuda, Munetaka ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Kanagawa Prefectural Cardiovascular and Respiratory Center Hospital   (Japan)

Author keywords

Cancer stem cell; Cd133; Lung adenocarcinoma; Prognosis; Stage I

Indexed keywords

CD133 ANTIGEN; GLYCOPROTEIN; KI 67 ANTIGEN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CELL PROLIFERATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PEPTIDES; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79955106228     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-485.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
3. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C. Clinical features of 5,628 primary lung cancer patients: experience at mayo clinic from 1997 to 2003. Chest 2005;128:452-462.
4. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, Nukiwa T, Miyaoka E; Japanese Joint Committee of Lung Cancer Registry. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 2008;3:46-52.
5. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19,702 stage I patients in the California cancer registry from 1989 to 2003. Cancer 2007;110:1532-1541.
6. Ginsberg RJ, Martini N. Non-small Cell Lung Cancer: Surgical Management. Thoracic Surgery. Edited by Pearson FG, Cooper JD, Deslauriers J, Ginsberg RJ, Hiebert CA, Patterson GA, Urschel HC. Philadelphia, PA, Churchill Livingstonem, 2002, pp.837-859.
7. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-9344.
8. Lobo NA, Shimono Y, Qian D, Clarke MF. The Biology of cancer stem cells. Annu Rev Cell Dev Biol 2007;23:675-699.
9. Rapp UR, Ceteci F, Schreck R. Oncogeneinduced plasticity and cancer stem cells. Cell Cycle 2008;7:45-51.
10. Kitamura H, Okudela K, Yazawa T, Sato H, Shimoyamada H. Cancer stem cell: implication in cancer biology and therapy with special reference to lung cancer. Lung Cancer 2009;66:275-281.
11. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110.
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115.
13. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006;351:820-824.
14. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
15. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-514.
16. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH. Oct-4 expression maintained cancer stem-like properties in lung cancerderived CD133-positive cells. PLoS One 2008;3:e2637.
17. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL. Aldehyde dehydrogenase 1 is a tumor stem cellassociated marker in lung cancer. Mol Cancer Res 2009;7:330-338.
18. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
19. Bertheau P, Cazals-Hatem D, Meignin V, de Roquancourt A, Vérola O, Lesourd A, Séné C, Brocheriou C, Janin A. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 1998;51:370-374.
20. DiVito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004;84:1071-1078.
21. Woo T, Okudela K, Yazawa T, Wada N, Ogawa N, Ishiwa N, Tajiri M, Rino Y, Kitamura H, Masuda M. Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer 2009;65:355-362.
22. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ, Sculier JP. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018-2025.
23. Zhao P, Li Yazhuo, Lu Yali. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC cancer 2010;10:218.
24. Takahashi S, Kamiyama T, Tomaru U, Ishizu A, Shida T, Osaka M, Sato Y, Saji Y, Ozaki M, Todo S. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010;24:1201-1212.
25. Yasuda H, Tanaka K, Saigusa S, Toiyama Y, Koike Y, Okugawa Y, Yokoe T, Kawamoto A, Inoue Y, Miki C, Kusunoki M. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemotherapy in rectal cancer. Oncol rep 2009;22:709-717.
26. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258-2264.
27. Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, Haga H, Matsushita M, Ozaki M, Matsuno Y, Todo S. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep 2010;24:537-546.
28. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, Ikemoto T. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gatroenterol 2010;45:896-902.
29. Liu Q, Li JG, Zheng XY, Jin F, Dong HT. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin Med J 2009;122:2763-2769.
30. Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G. CD133 antigen expression in ovarian cancer. BMC Cancer 2009;9:221.
31. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G. Highly tumoligenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Scia USA 2009;106:16281-16286.
32. Li F, Zeng H, Ying K. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non small cell lung carcinomas. Med Oncol 2010 Aug 18 [Epub ahead of print].
33. Tsuchiya T, Akamine S, Muraoka M, Kamohara R, Tsuji K, Urabe S, Honda S, Yamasaki N. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy. Lung Cancer 2007;56:341-348.
34. Bodendorf MO, Haas V, Laberke HG, Blumenstock G, Wex P, Graeter T. Prognostic value and therapeutic consequences of vascular invasion in non-small cell lung carcinoma. Lung Cancer 2009;64:71-78.
35. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010;126:950-958.
36. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC cancer 2008;8:48.
37. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010;70:719-729.
38. Karbanová J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerová H, Jászai J, Ehrmann J, Kolár Z, Liebers C, Arl S, Subrtová D, Freund D, Mokry J, Huttner WB, Corbeil D. the stem cell marker CD133 (prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 2008;56:977-993.
39. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2010 Jun 25 [Epub ahead of print]
40. Zhang HZ, Wei YP, Wang M, Wu C, Yang YQ, Chen J, Cao YK. Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2007;27:696-699.
41. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008;14:123-129.
42. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. A CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-1289.
43. Giordano A, de Falco G, Rubin E, Rubin R. Neoplasia. Rubin's Pathology. Edited by Rubin R, Strayer DS. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp.137-176.
44. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, de Maria R. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008;14:8205-8212.